The Economic Survey 2024-25 reveals an expected increase in Goa's population to 15.96 lakh by 2025 but highlights worrying ...

In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

The rate of maternal mortality related to cardiovascular causes more than doubled between 1999 and 2022 in the United States, ...

The risk of dying from heart complications is significantly higher in the first 2 years after a colorectal cancer diagnosis, ...

One study found that Black women were 3 times more likely to die of maternal deaths due to cardiovascular disease than White ...

Key Takeaways A healthy plant-based diet can extend the lives of people struggling with heart disease, diabetes and ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Colon cancer is the second leading cause of cancer deaths in the U.S., and a new study shows it may also raise the risk of ...